Nab-paclitaxel: A flattering facelift

Highlights • We examine the pharmacokinetic (PK) and pharmacodynamic (PD) profile of nab-paclitaxel and compare them to conventional paclitaxel. • Those differences in PK/PD properties could explain the improve in treatment efficacy and reduce side-effects. • We explain deeply the clinical developme...

Full description

Saved in:
Bibliographic Details
Published inCritical reviews in oncology/hematology Vol. 92; no. 3; pp. 166 - 180
Main Authors Viúdez, A, Ramírez, N, Hernández-García, I, Carvalho, F.L, Vera, R, Hidalgo, M
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ireland Ltd 01.12.2014
Subjects
Albumins - pharmacology
Albumins - therapeutic use
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biological Transport
Biomarkers
Breast cancer
Clinical Trials as Topic
Drug Evaluation, Preclinical
Hematology, Oncology and Palliative Medicine
Humans
Nab-paclitaxel
Nanomedicine
Nanotechnology
Neoplasms - drug therapy
Paclitaxel - pharmacology
Paclitaxel - therapeutic use
Pancreatic cancer
SPARC
Treatment Outcome
Breast cancer
SPARC
Nanomedicine
Pancreatic cancer
Nab-paclitaxel
Nanotechnology
Online AccessGet full text

Cover

More Information
Summary:Highlights • We examine the pharmacokinetic (PK) and pharmacodynamic (PD) profile of nab-paclitaxel and compare them to conventional paclitaxel. • Those differences in PK/PD properties could explain the improve in treatment efficacy and reduce side-effects. • We explain deeply the clinical development of nab-paclitaxel in breast cancer, non-small-cell-lung-cancer, pancreatic cancer and other scenarios as ovarian, melanoma and bladder carcinoma. • We review different molecules that could have a role as predictive/resistance biomarkers for nab-paclitaxel.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2014.06.001